Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 6, 2001, Pages 905-910

  Kislinger, Thomas ^a   Tanji, Nozomu ^a   Wendt, Thoralf ^a   Qu, Wu ^a   Lu, Yan ^a   Ferran Jr , Luis J ^a   Taguchi, Akihiko ^a   Olson, Kim ^a   Bucciarelli, Loredana ^a   Goova, Mouza ^a   Hofmann, Marion A ^a   Cataldegirmen, Guellue ^a   D'Agati, Vivette ^a   Pischetsrieder, Monika ^a   Stern, David M ^a   Schmidt, Ann Marie ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Atherosclerosis; Diabetes; Glycation; Nephropathy; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN E; CALGRANULIN; COLLAGEN TYPE 4; CYTOKINE; FIBRONECTIN; PROTEIN S 100; STREPTOZOCIN; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIABETIC ANGIOPATHY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TISSUE CULTURE;

EID: 0035715443     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.6.905     Document Type: Article

References (37)

1. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface
2. Cloning and expression of RAGE: A cell surface receptor for advanced glycosylation end products of proteins
3. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
4. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
5. Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice
6. Large and sustained induction of chemokines during impaired wound healing in diabetic mouse: Prolonged persistence of neutrophils and macrophages during the late phase of repair
7. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides
8. Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE)
9. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions
10. Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging
11. Carboxymethyllysine protein adduct is a major immunological epitope in proteins modified with AGEs of the Maillard reaction
12. Carboxymethyllysine is a dominant AGE antigen in tissue proteins
13. ε (carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression
14. The dark side of glucose
15. The expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease
16. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats
17. Spontaneous hypercho-lesterolemia and arterial lesions in mice lacking apolipoprotein E
18. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
19. Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus
20. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in stz-induced diabetic mice
21. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products
22. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1): A potential mechanism for the accelerated vasculopathy of diabetes
23. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects
24. Diabetes and cardiovascular disease: The Framingham Study
25. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
26. Endothelial nuclear factor kB and the initiation of the atherosclerotic lesion
27. Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-β as a key mediator
28. Suppression of experimental glomeru-lonephritis by antiserum against TGFβ
29. The S100 protein family: History, function, and expression
30. The S100 family of EF-hand calcium-binding proteins: Functions and pathology
31. Atherosclerotic lesions of apolipoprotein E deficient mice contain cells expressing S100 protein
32. Significance of serum S100 release after coronary artery bypass grafting
33. S100A1 and S100B expression and target proteins in type 1 diabetes
34. The role of macrophages in diabetes glomerulosclerosis
35. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: Dysregulation of cytokine, and toll-like receptor 2 and 4 gene expression
36. NF-kB, a mediator of lipopolysaccharide effects
37. Activated NF-kB is present in atherosclerotic lesions